TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27992833

Group type: COMPARATOR
Intervention: Control (minimal drinking quantity and frequency questions)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Consequences (College Alcohol Problems Scale; CAPS‐r)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Norms (Drinking Norms Rating Form)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Diagnostic (Alcohol Use Disorders Identification Test)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Combined (all themes)
Number of subjects: 290
Study: 26264702

Group type: EXPERIMENTAL
Intervention: Evacetrapib 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evacetrapib 300 mg
Number of subjects: 0
Study: 23824078

Group type: EXPERIMENTAL
Intervention: Elderly Adi women
Number of subjects: 531
Study: 21679043

Group type: EXPERIMENTAL
Intervention: IV diclofenac 3.75 mg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: IV diclofenac 37.5 mg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: IV diclofenac 75 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 19628193

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall patients (statin treatments)
Number of subjects: 100
Study: 16641127

Group type: EXPERIMENTAL
Intervention: Echinacea treatment for rhinovirus infection
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: WURSS questionnaire
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Jackson questionnaire
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: WURSS and Jackson questionnaires
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Wisconsin Upper Respiratory Symptom Survey
Number of subjects: 399
Study: 15574077

Group type: EXPERIMENTAL
Intervention: Hyperhydrated state induced by glycerol ingestion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control state
Number of subjects: 8
Study: 11065035

Group type: EXPERIMENTAL
Intervention: Acidotic group (14 infants)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (78 deliveries)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nucleated red blood cell counts
Number of subjects: 92
Study: 9190237

Group type: EXPERIMENTAL
Intervention: Cytograms and tissue sections of nasal polyps and mucosa in patients with allergic rhinitis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cytograms and tissue sections of nasal polyps and mucosa in patients with nonallergic eosinophilic rhinitis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cytograms and biopsies in control group (20 asymptomatic persons)
Number of subjects: 30
Study: 1872460

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopentone (4 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 30
Study: 6638026

Group type: EXPERIMENTAL
Intervention: Pharmacist-prescriber group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Physician-prescriber group
Number of subjects: 81
Study: 30712739

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation and Interactive Guided Imagery (PMR-IGI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 104
Study: 28235529

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus 2 μg/kg dexmedetomidine, 1 mL/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.125% bupivacaine, 1 mL/kg
Number of subjects: 60
Study: 25367012

Group type: EXPERIMENTAL
Intervention: Software reports (SR)
Number of subjects: 111
Study: 24203450

Group type: EXPERIMENTAL
Intervention: ZST (1.0 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ZST (1.75 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ZST (3.5 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 22482874

Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 222
Study: 20494961

Group type: EXPERIMENTAL
Intervention: Fulvestrant approved dose (AD)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fulvestrant loading dose (LD)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fulvestrant high dose (HD)
Number of subjects: 143
Study: 18819457

Group type: EXPERIMENTAL
Intervention: Cicatridine
Number of subjects: 319
Study: 15849476

Group type: EXPERIMENTAL
Intervention: Intraperitoneal tinzaparin (4,500 anti-Xa IU)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 21
Study: 12373661

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 0
Study: 10604492

Group type: EXPERIMENTAL
Intervention: Aggressive glucose control
Number of subjects: 26
Study: 11224347

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 or 50mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5g/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Naltrexone pretreatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2198001

Group type: EXPERIMENTAL
Intervention: Breast conservation therapy
Number of subjects: 499

Group type: COMPARATOR
Intervention: No locoregional recurrence
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Locoregional recurrence
Number of subjects: 499
Study: 1258750

Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine (4.5 mg/kg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31306396

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam plus metronidazole
Number of subjects: 83

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 83
Study: 28718248

Group type: EXPERIMENTAL
Intervention: 2% diltiazem cream
Number of subjects: 184

Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate cream
Number of subjects: 184
Study: 25770048

Group type: EXPERIMENTAL
Intervention: Structured presentation (S group)
Number of subjects: 105
Study: 24136281

Group type: EXPERIMENTAL
Intervention: 1.5 mm thick soft splint
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2 mm thick resin stability splint
Number of subjects: 25

Group type: COMPARATOR
Intervention: 4 mm thick resin stability splint
Number of subjects: 25

Group type: COMPARATOR
Intervention: buccolingual mock splint
Number of subjects: 25

Group type: COMPARATOR
Intervention: no splint
Number of subjects: 25
Study: 21606974

Group type: EXPERIMENTAL
Intervention: 5 mg A3309
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: 10 mg A3309
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: 15 mg A3309
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 19388900

Group type: EXPERIMENTAL
Intervention: meperidine 1%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: meperidine 2%
Number of subjects: 18

Group type: COMPARATOR
Intervention: saline
Number of subjects: 18
Study: 22878195

Group type: EXPERIMENTAL
Intervention: 300 mg of Pueraria flower extract (PFE)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 200 mg of Pueraria flower extract (PFE)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 16786177

Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling
Number of subjects: 49

Group type: COMPARATOR
Intervention: Vitrectomy without ILM peeling
Number of subjects: 49

Group type: COMPARATOR
Intervention: Comparison of visual acuity change between Group I and Group II
Number of subjects: 49
Study: 12654763

Group type: EXPERIMENTAL
Intervention: telithromycin 800 mg once daily
Number of subjects: 3935
Study: 9793807

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (25 micrograms) without prior i.v. fluid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intrathecal fentanyl (25 micrograms) with prior i.v. fluid (500 ml of lactated Ringer's solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluid infusion (500 ml of lactated Ringer's solution)
Number of subjects: 30
Study: 7648764

Group type: EXPERIMENTAL
Intervention: E3810 (20 mg once daily for 7 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Omeprazole (20 mg once daily for 7 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: E3810
Number of subjects: 15

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: E3810 and Omeprazole
Number of subjects: 15
Study: 2771866

Group type: EXPERIMENTAL
Intervention: Disopyramide single bolus injection (150 mg) over 5 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Disopyramide infusion (28.2 mg/h to steady state)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Disopyramide single bolus injection (150 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Disopyramide (both methods)
Number of subjects: 8
Study: 1272721

Group type: EXPERIMENTAL
Intervention: Intimate self-disclosure
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Nonintimate self-disclosure
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (no disclosure)
Number of subjects: 65
Study: 12078386

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 3 g vitamin C
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100 ml 0.9% saline solution (placebo)
Number of subjects: 40
Study: 29389836

Group type: COMPARATOR
Intervention: CON/ECC (conventional concentric/eccentric strength training)
Number of subjects: 37
Study: 27212612

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis before skin incision (A)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Antibiotic prophylaxis after umbilical cord clamping (C)
Number of subjects: 279
Study: 24771017

Group type: EXPERIMENTAL
Intervention: Positive Choices (PC) intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comprehensive standard of care (C-SoC)
Number of subjects: 102
Study: 23095627

Group type: EXPERIMENTAL
Intervention: Primary anastomosis (PA) with diverting ileostomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Hartmann's procedure (HP)
Number of subjects: 62
Study: 20166406

Group type: EXPERIMENTAL
Intervention: TPH Spectrum/XenoIII (TS) restoration group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Synergy Compact/One Coat (SC) restoration group
Number of subjects: 32
Study: 18586991

Group type: EXPERIMENTAL
Intervention: Implementation intentions training (N=40)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No implementation intentions training (N=38)
Number of subjects: 78
Study: 16375216

Group type: EXPERIMENTAL
Intervention: Mouth dissolving tablets (Nimulid-MD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nimulid suspension
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mouth dissolving tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 12
Study: 12194075

Group type: EXPERIMENTAL
Intervention: Fluorescein Meniscus Time (FMT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Schirmer's Test (ST)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Tear Break Up Time (TBUT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control Group (15 subjects tested for reproducibility of FMT)
Number of subjects: 62
Study: 10206567

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral techniques (16-hour, 8-week class)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal treatment (home-study manual)
Number of subjects: 0
Study: 7628887

Group type: EXPERIMENTAL
Intervention: 8 micrograms/kg dofetilide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 12 micrograms/kg dofetilide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dofetilide (8 and 12 micrograms/kg)
Number of subjects: 16
Study: 2930443

Group type: EXPERIMENTAL
Intervention: Structured research-based marital therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clinically flexible marital therapy
Number of subjects: 30
Study: 69192

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional schedule in air (Control)
Number of subjects: 0
Study: 31238828

Group type: EXPERIMENTAL
Intervention: Genetically determined risk of depression (1-SD increase)
Number of subjects: 6021
Study: 28441365

Group type: EXPERIMENTAL
Intervention: Silicone tube
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Beschitin‐F
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aquacel1‐Ag
Number of subjects: 66
Study: 25311148

Group type: EXPERIMENTAL
Intervention: ASSIST
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: ASSIST-Lite
Number of subjects: 525
Study: 23905228

Group type: EXPERIMENTAL
Intervention: Parental presence
Number of subjects: 130
Study: 21742301

Group type: EXPERIMENTAL
Intervention: Intralesional methotrexate infiltration (single dose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 25
Study: 19738565

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic therapy (TcMT), 10 sessions, bitemporal method, modulation frequency 1-10 Hz
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo sessions of TcMT with magnetic power supply switched off
Number of subjects: 80
Study: 16320011

Group type: EXPERIMENTAL
Intervention: Catheter‐mediated femoral nerve block with 1% prilocaine (40 ml) and post‐operatively 0.2% ropivacaine (30 ml) 6 hourly
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous metamizol (1 g) and oral tilidine (100 mg) + naloxone (8 mg), with reduced doses for patients aged 90 years or more
Number of subjects: 100
Study: 14571608

Group type: EXPERIMENTAL
Intervention: Composite Rhodiolae (CR) administered 4 g daily for 7-10 days before and 5-7 days after the operation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 76
Study: 10964859

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8985019

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg i.v. weekly with forced hydration during radiotherapy (CM group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Radiotherapy only (RT group)
Number of subjects: 83
Study: 1478406

Group type: EXPERIMENTAL
Intervention: Mesalazine controlled-release suppository 1 g once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6141898

Group type: EXPERIMENTAL
Intervention: SKF 93479 (20, 40, 60, and 80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SKF 93479 (80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SKF 93479
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine (300 mg)
Number of subjects: 0
Study: 30669147

Group type: EXPERIMENTAL
Intervention: Calcimimetic cinacalcet
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1494
Study: 29397627

Group type: EXPERIMENTAL
Intervention: Transcystic biliary drainage
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nasobiliary drainage
Number of subjects: 106
Study: 27273941

Group type: EXPERIMENTAL
Intervention: 131I‐chTNT and PMCT
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemotherapy with docetaxel and cisplatin and three‐dimensional conformal radiotherapy
Number of subjects: 96
Study: 25239625

Group type: EXPERIMENTAL
Intervention: Email intervention (personalized emails reminding of legal requirement)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no email intervention)
Number of subjects: 190
Study: 23259231

Group type: EXPERIMENTAL
Intervention: Group voice and singing intervention (60 minutes, once a week for 20 weeks)
Number of subjects: 10
Study: 21144025

Group type: EXPERIMENTAL
Intervention: 18-month behavioral weight loss intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study: 18072836

Group type: EXPERIMENTAL
Intervention: Gain-framed messages with sustained-release bupropion (300 mg/day) for 7 weeks
Number of subjects: 258

Group type: COMPARATOR
Intervention: Loss-framed messages with sustained-release bupropion (300 mg/day) for 7 weeks
Number of subjects: 258
Study: 15449047

Group type: EXPERIMENTAL
Intervention: 131I administration (3.7 GBq)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: In vitro irradiation at doses of 0.5, 1 and 2 Gy
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 30
Study: 12403316

Group type: EXPERIMENTAL
Intervention: ICP10deltaPK vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10235427

Group type: EXPERIMENTAL
Intervention: Napsagatran 5 mg/h
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Napsagatran 9 mg/h
Number of subjects: 105

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Napsagatran 5 mg/h and 9 mg/h
Number of subjects: 105
Study: 8917236

Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 22505
Study: 1887351

Group type: EXPERIMENTAL
Intervention: 5 mg gentamicin
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 10 mg gentamicin
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 20 mg gentamicin
Number of subjects: 89
Study: 6651314

Group type: EXPERIMENTAL
Intervention: Oral methoxsalen and total body irradiation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Topical applications of methoxsalen or oral methoxsalen combined with local irradiation of the scalp
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PUVA treatment (psoralens and UV‐A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with long‐lasting alopecia
Number of subjects: 23
Study: 29245022

Group type: EXPERIMENTAL
Intervention: Nurse case‐managed program combined with contingency management (NCM + CM)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Standard education plus contingency management (SE + CM)
Number of subjects: 451
Study: 28320258

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC) in women
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Concentric exercise (CONC) in men
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC) in men
Number of subjects: 20
Study: 26184556

Group type: EXPERIMENTAL
Intervention: Chronic inflammation
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Acute inflammation
Number of subjects: 886
Study: 23020819

Group type: EXPERIMENTAL
Intervention: Probiotic-containing powder (daily dose of minimum 1 billion colony-forming units of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12®), n=114
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo, n=117
Number of subjects: 231
Study: 21078150

Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms in women
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms in women after 12 months
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms in men
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms in men after 12 months
Number of subjects: 1978
Study: 18186151

Group type: EXPERIMENTAL
Intervention: Prenatal screening test offer
Number of subjects: 59
Study: 16356192

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 57
Study: 15311008

Group type: EXPERIMENTAL
Intervention: Calcium citrate (400 mg calcium twice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Potassium citrate (20 mEq twice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Calcium citrate and potassium citrate (at same doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10914793

Group type: EXPERIMENTAL
Intervention: GTR+ABB (cellulose membrane + bovine-derived anorganic bone)
Number of subjects: 14

Group type: COMPARATOR
Intervention: GTR (membrane alone)
Number of subjects: 14
Study: 9328950

Group type: EXPERIMENTAL
Intervention: High alkali dialysate (HA; lactate 40 mmol/liter)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low alkali dialysate (LA; lactate 35 mmol/liter)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High alkali dialysate (HA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low alkali dialysate (LA)
Number of subjects: 200
Study: 8403647

Group type: EXPERIMENTAL
Intervention: Patellar tendon graft (PT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Leeds-Keio graft (LK)
Number of subjects: 55
Study: 3519242

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3277579

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 29743101

Group type: EXPERIMENTAL
Intervention: Perioperative, algorithm-driven hemodynamic therapy based on individualized fluid status and cardiac output optimization using pulse-pressure variation (PPV) and pulse-contour analysis (ProAQT© device).
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard local care based on established basic hemodynamic treatment.
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Perioperative, algorithm-driven hemodynamic therapy.
Number of subjects: 380
Study: 27413130

Group type: COMPARATOR
Intervention: Vitamin D 600 IU/d
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Vitamin D 3750 IU/d
Number of subjects: 257
Study: 24712855

Group type: EXPERIMENTAL
Intervention: Parent-focused treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conjoint family‐based treatment
Number of subjects: 100
Study: 22993169

Group type: EXPERIMENTAL
Intervention: Oral appliance (OA) therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Objective measurement of OA compliance
Number of subjects: 51

Group type: COMPARATOR
Intervention: Self-reported OA compliance data
Number of subjects: 51
Study: 20498212

Group type: EXPERIMENTAL
Intervention: Initial combination therapy
Number of subjects: 465

Group type: COMPARATOR
Intervention: Initial monotherapy
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Matrix model
Number of subjects: 465